Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Clinical implementation of PARP inhibitors

What is the true impact of PARP inhibitors in clinical practice?


19 Oct 2018


Clinical implementation of PARP inhibitors


Cytotoxic Therapy

Tumour Site

Breast Cancer


Andrew Tutt


A. Tutt

Author affiliations

  • Breast Cancer Now Research Unit, The Institute of Cancer Research (ICR), SW7 3RP - London/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.